Piramal Healthcare prioritizes organic growth for the next 4-5 years. The company will explore licensing and product acquisitions in complex generics and consumer healthcare. Piramal aims for $2 billion revenue by FY30, focusing on differentiated offerings like antibody-drug conjugates. Expansion includes investments in US facilities. The company reported Q1 FY26 results with a net loss of Rs 82 crore.